What is Commit Biologics?
Founded in 2021 as a spin-out from Aarhus University, Commit Biologics leverages over three decades of academic research in complement system biology. The company specializes in antibody development, aiming to create a new class of treatments for challenging conditions such as cancer and autoimmune diseases. Its foundation in a globally recognized research institution provides a strong scientific basis for its therapeutic ambitions.
How much funding has Commit Biologics raised?
Commit Biologics has raised a total of $22.2M across 1 funding round:
Angel/Seed
$22.2M
Angel/Seed (2025): $22.2M with participation from Bioqube Ventures and Novo Holdings
Key Investors in Commit Biologics
Bioqube Ventures
Bioqube Ventures is a global life sciences investment firm that focuses on transforming scientific discoveries into innovative medicines. They invest in companies developing first- or best-in-class therapeutics to meet significant unmet medical needs, supporting companies from inception through early clinical milestones.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999 and headquartered in Hellerup, Denmark. It plays a significant role in supporting life science innovation.
What's next for Commit Biologics?
The recent major enterprise-level funding positions Commit Biologics for accelerated growth and the advancement of its therapeutic pipeline. This strategic investment will likely fuel further research and development, potentially enabling the company to move towards clinical trials and expand its operational capacity. The backing from prominent investors suggests confidence in the company's innovative approach to complex diseases.
See full Commit Biologics company page
